TY - JOUR
T1 - Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma
AU - Abadi, Uri
AU - Peled, Lee
AU - Gurion, Ronit
AU - Rotman-Pikielny, Pnina
AU - Raanani, Pia
AU - Ellis, Martin H.
AU - Rozovski, Uri
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/10/15
Y1 - 2019/10/15
N2 - The reported prevalence of hypercalcemia at diagnosis in non-Hodgkin-lymphoma ranges between 1.3% and 7.4%. These studies included all patients, regardless of lymphoma subtype. We performed a retrospective case-control study to determine the prevalence of hypercalcemia at time of diagnosis in patients with diffuse large B-cell lymphoma (DLBCL). Among 250 newly diagnosed patients, 46 (18%) had hypercalcemia. When compared with age-sex matched patients and normal calcium levels, those with hypercalcemia had higher levels of LDH, lower levels of albumin and more advanced stage. These differences were translated to shorter progression-free-survival and overall survival, but only in patients with hypercalcemia and low levels of parathyroid hormone (PTH). These findings suggest that in newly diagnosed patients with DLBCL, hypercalcemia is more frequent than previously appreciated. Furthermore, lymphoma-related but not primary hyperparathyroidism-related hypercalcemia is associated with adverse prognostic factors and adverse clinical outcomes in DLBCL. Hence, PTH should be obtained in patients with DLBCL and hypercalcemia at diagnosis.
AB - The reported prevalence of hypercalcemia at diagnosis in non-Hodgkin-lymphoma ranges between 1.3% and 7.4%. These studies included all patients, regardless of lymphoma subtype. We performed a retrospective case-control study to determine the prevalence of hypercalcemia at time of diagnosis in patients with diffuse large B-cell lymphoma (DLBCL). Among 250 newly diagnosed patients, 46 (18%) had hypercalcemia. When compared with age-sex matched patients and normal calcium levels, those with hypercalcemia had higher levels of LDH, lower levels of albumin and more advanced stage. These differences were translated to shorter progression-free-survival and overall survival, but only in patients with hypercalcemia and low levels of parathyroid hormone (PTH). These findings suggest that in newly diagnosed patients with DLBCL, hypercalcemia is more frequent than previously appreciated. Furthermore, lymphoma-related but not primary hyperparathyroidism-related hypercalcemia is associated with adverse prognostic factors and adverse clinical outcomes in DLBCL. Hence, PTH should be obtained in patients with DLBCL and hypercalcemia at diagnosis.
KW - Diffuse large B-cell lymphoma
KW - hypercalcemia
KW - hyperparathyroidism
UR - http://www.scopus.com/inward/record.url?scp=85067561034&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1620946
DO - 10.1080/10428194.2019.1620946
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31167584
AN - SCOPUS:85067561034
SN - 1042-8194
VL - 60
SP - 2922
EP - 2926
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -